Sirtuins, NAD+, and Caloric Restriction: What the Molecular Pathway Research Actually Shows

Jun 8, 2026

Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment. Not medical advice. Consult a qualified healthcare professional before changing your diet, caloric intake, or supplement regimen, particularly if you are managing a chronic condition or taking prescription medications.

One pattern keeps appearing across longevity research: organisms that eat less tend to live longer under controlled conditions. Caloric restriction extends lifespan across yeast, roundworms, fruit flies, and rodents. It does not do so predictably or consistently across all species, and evidence from human aging trials is limited and preliminary. The question researchers have spent the past two decades pursuing is what the molecular mediators of this effect might be — and sirtuins, as NAD+-dependent enzymes that respond to cellular energy state, are a central part of that story.

How central they are in humans, at clinical-outcome level, is a harder and still-open question.

TL;DR

Sirtuins (SIRT1–SIRT7 in mammals) are a family of NAD+-dependent deacylase enzymes — they use NAD+ to remove chemical modifications from proteins, with downstream effects on gene expression, DNA repair, and metabolic regulation
SIRT1, SIRT3, and SIRT6 are the three sirtuins most studied in aging contexts; they operate in the nucleus and mitochondria with distinct substrate profiles
NAD+ availability directly limits sirtuin activity — cellular NAD+ levels are correlated with lower levels in aged tissue and with caloric surplus, and are correlated with higher levels under caloric restriction conditions; this is the molecular link between eating patterns and sirtuin function
Caloric restriction in model organisms robustly activates sirtuins and extends healthy lifespan; the most rigorous human caloric restriction trial (CALERIE Phase 2) showed improvements in cardiometabolic biomarkers without establishing longevity outcomes
NMN and NR, as NAD+ precursors, raise cellular NAD+ in human studies — whether this downstream activates sirtuins at clinically meaningful levels in humans is mechanistically coherent but not confirmed at clinical-outcome level
Japan’s hara hachi bu practice and shojin ryori (Buddhist temple cuisine) represent culturally embedded caloric moderation; attributing their demographic associations to sirtuin activation specifically requires direct measurement that current research has not provided

What sirtuins are

Sirtuins were originally identified in yeast, where the founding member — Sir2 (Silent Information Regulator 2) — was characterized in the 1990s as a deacetylase involved in gene silencing. Guarente and colleagues at MIT subsequently found that Sir2 mediates a portion of the lifespan extension observed in calorie-restricted yeast, connecting a single enzyme family to both caloric state and aging processes.

Mammals carry seven sirtuin paralogs (SIRT1–SIRT7), each with distinct cellular locations, substrate preferences, and documented functions. Three have accumulated the most aging-relevant evidence:

SIRT1 operates in the nucleus and deacetylates transcription factors and co-regulators including PGC-1α (a master regulator of mitochondrial biogenesis), FOXO3 (a transcription factor associated with stress resistance and longevity in centenarian genetic research), and p53. SIRT1 activity is linked to autophagy induction through deacetylation of ATG proteins — the molecular connection between sirtuin function and the autophagy pathway discussed in the Ohsumi Nobel research article. SIRT1 uses NAD+ as a co-substrate in each catalytic cycle and its activity is suppressed when cellular NAD+ is depleted.

SIRT3 is the primary mitochondrial sirtuin, deacetylating and activating enzymes in the tricarboxylic acid (TCA) cycle and electron transport chain — including LCAD (fatty acid oxidation), IDH2, and superoxide dismutase 2 (MnSOD, the main mitochondrial antioxidant enzyme). SIRT3 expression is lower in aged human muscle and liver tissue compared to younger samples in several cross-sectional datasets, though whether this decline is a driver or a consequence of cellular aging is not established.

SIRT6 specializes in DNA double-strand break repair and metabolic regulation. It deacetylates histone marks (H3K9ac and H3K56ac) at damage sites to facilitate repair and separately suppresses HIF-1α-driven glycolytic gene expression. SIRT6 overexpression extends mouse lifespan; SIRT6 knockout produces a severe accelerated aging phenotype in rodents. SIRT6 variants have been examined in human longevity cohort analyses with inconsistent results across populations.

How the NAD+ cycle connects to this picture

All sirtuins consume NAD+ as a co-substrate — not as a conventional cofactor, but as a reactant: one NAD+ molecule is consumed per catalytic cycle, producing nicotinamide (NAM) as a byproduct. Cellular NAD+ must therefore be continuously regenerated for sirtuin activity to be sustained.

The primary regeneration route in most mammalian tissues is the salvage pathway: NAM is converted to NMN (nicotinamide mononucleotide) by NAMPT (nicotinamide phosphoribosyltransferase), and NMN is then converted to NAD+ by NMNAT enzymes. NAMPT is the rate-limiting step in this pathway. NAMPT activity is correlated with lower levels in aged tissue in rodent studies — whether this decline drives lower NAD+ or reflects it is under investigation.

Cellular NAD+ levels in aged human tissue are consistently lower than in younger tissue in cross-sectional measurements (peripheral blood mononuclear cells, skeletal muscle biopsies). Lower NAD+ would — if the pathway behaves as preclinical work indicates — reduce SIRT1 and SIRT3 activity, constrain PGC-1α-driven mitochondrial biogenesis, impair autophagy induction, and limit SIRT6-mediated DNA repair. This is the mechanistic logic underlying NAD+ repletion strategies, whether through caloric restriction or precursor supplementation.

The logic is well-grounded in preclinical work. Whether restoring NAD+ levels in humans through supplementation or dietary change produces clinically meaningful effects on aging trajectories is a separate question that remains at the preliminary evidence stage.

Caloric restriction and sirtuin activation

Caloric restriction activates sirtuins through overlapping routes. Reduced caloric intake lowers circulating insulin and IGF-1, suppresses mTOR signaling, and activates AMPK — conditions that reduce biosynthetic NAD+ consumption and shift cellular metabolism toward catabolism. The net effect on cellular NAD+ levels under caloric restriction is an increase, supporting sirtuin activity. NAMPT expression appears to increase under caloric restriction in rodent studies, amplifying the effect through the salvage pathway.

The caloric restriction lifespan extension data in model organisms is robust but shows meaningful species specificity. The effect is most consistent in short-lived organisms (yeast, C. elegans, Drosophila) and is more variable in rodents depending on strain, baseline diet, and dietary composition. In rhesus macaques, two major long-term studies — the NIA trial and the Wisconsin WNPRC trial — produced divergent mortality results. Subsequent analysis attributed much of the difference to the control diet compositions: the WNPRC controls ate an ad libitum diet that was itself metabolically suboptimal, making the restriction effect larger by comparison. This illustrates that restriction effects in primates depend substantially on dietary quality, not only on caloric quantity.

CALERIE Phase 2 is the most relevant human dataset. This two-year randomized controlled trial enrolled 218 non-obese adults aged 21–50 and targeted 25% caloric restriction relative to baseline intake (mean achieved restriction was closer to 12%). Published findings in JAMA Internal Medicine (2015) and companion papers documented improvements in cardiometabolic risk markers — LDL cholesterol, blood pressure, inflammatory cytokines, insulin sensitivity — without caloric deficits severe enough to raise safety concerns in this population. The trial did not measure sirtuin activity or cellular NAD+ levels as primary endpoints; whether its metabolic improvements were sirtuin-mediated is mechanistically plausible but not established by the trial design.

Japan’s caloric moderation practices

Two Japanese cultural practices sit at the intersection of this research area: hara hachi bu and shojin ryori.

Hara hachi bu — stopping eating at roughly 80% satiety — is documented as widespread practice among traditional Okinawan communities and appears in retrospective dietary data from the Okinawa Centenarian Study alongside lower overall caloric intake. Whether this practice reliably produces AMPK activation or elevated NAD+ sufficient to alter sirtuin activity in practitioners has not been measured. The centenarian cohort data identifies an association between restrained eating patterns and longevity outcomes; it does not identify the molecular mediators. The caloric and demographic picture is covered in detail in Okinawa hara hachi bu and caloric restriction science.

Shojin ryori — Zen Buddhist vegetarian temple cuisine — is structurally low in caloric density, high in fiber, seasonal vegetables, and tofu, with minimal oil. A traditional shojin meal served at monasteries in Koyasan or Eiheiji typically provides 1,000–1,400 kcal. Whether this pattern activates caloric restriction biochemistry depends on individual baseline intake and the duration of the practice. Shojin ryori is a contemplative and ethical dietary form, not a controlled intervention; the pathway connection to sirtuin biology is biologically plausible but has not been directly measured in monastic populations.

Both practices are better understood as dietary pattern signals with indirect evidence connecting them to metabolic states associated with sirtuin activation, rather than as established sirtuin modulators. The mechanistic inference is reasonable; the evidentiary claim requires more measurement than currently exists.

NMN, resveratrol, and the supplementation picture

Two supplement categories are most frequently discussed alongside sirtuin research.

NMN and NR replenish the NAD+ pool — NMN directly via the salvage pathway, NR via conversion to NMN. Both raise measurable NAD+ in human trials at studied doses (250–1000 mg/day for NMN; 250–500 mg/day for NR). That NAD+ levels rise in peripheral blood is established. Whether this translates to meaningfully elevated SIRT1 or SIRT3 activity in aging-relevant tissues — muscle, liver, brain — and whether any such elevation affects aging trajectories is the open question. The primary human NMN trials, Yoshino et al. 2021 (Washington University) and Igarashi et al. 2022 (Keio University), showed improvements in insulin sensitivity and muscle function endpoints respectively, without measuring sirtuin activity as a primary outcome. The full NMN evidence picture, including brand data, is covered in NMN Supplements and Japanese Research: What the RCTs Actually Show. NMN supplements are available through Amazon from several manufacturers with published clinical data.

Resveratrol was proposed as a direct SIRT1 activator following Howitz et al. (Nature, 2003), which found resveratrol extended yeast lifespan through Sir2. The direct SIRT1 activation claim was substantially revised in subsequent work — the original assay used a fluorescent substrate that may have produced an artifactual result; with native substrates, resveratrol’s relationship to SIRT1 is more indirect. Resveratrol also activates AMPK through other mechanisms (PDE4 inhibition, indirect effects on cellular energy balance), which could affect NAD+ availability through that route. Human trials on resveratrol for longevity-relevant endpoints remain preliminary. Resveratrol is derived from Japanese knotweed (Reynoutria japonica) in most supplement preparations — the plant is native to East Asia. Options are available on Amazon.

Both categories carry interaction potential: NMN may interact with certain diabetes medications; resveratrol may interact with blood thinners and chemotherapy agents. These interactions are not universal risks, but they warrant a conversation with a clinician before beginning supplementation, not after.

What the evidence does not yet establish

Several claims circulate in coverage of sirtuin biology that are not well supported by current data.

That sirtuin supplementation extends human lifespan. No human RCT has measured lifespan as a primary endpoint for any sirtuin-activating compound. CALERIE Phase 2 measured cardiometabolic biomarkers over two years in non-obese young-to-middle-aged adults. That is not a lifespan study, and its population limits direct generalization to older or less healthy adults.

That caloric restriction in humans activates sirtuins at a measurable level. CALERIE Phase 2 improved metabolic markers but did not measure sirtuin activity or cellular NAD+ as primary outcomes. The inference that its benefits are sirtuin-mediated is mechanistically plausible but not established by the trial evidence.

That traditional Japanese eating practices work specifically through sirtuin activation. Hara hachi bu and shojin ryori may produce metabolic states consistent with AMPK activation and elevated cellular NAD+, but this has not been measured in centenarian populations. The population associations are real; the molecular mechanism requires direct measurement to confirm.

These gaps do not invalidate the research program. The sirtuin-NAD+ pathway is among the better-characterized molecular candidates for understanding caloric restriction’s effects on aging biology. The distinction between “mechanistic pathway established in model organisms” and “human aging RCT evidence established” is the discipline this literature requires — and which the most rigorous researchers in the field consistently apply.

Practical framing

If the sirtuin-NAD+ pathway interests you from an applied standpoint, a few directions have more grounding than others.

Caloric moderation — the kind embedded in hara hachi bu or a shojin-influenced meal structure — is well-tolerated, costs nothing, and is consistent with CALERIE Phase 2’s metabolic findings and the broader caloric restriction literature. Anyone managing type 2 diabetes, eating disorders, or conditions requiring stable caloric intake should approach any deliberate restriction in consultation with a clinician.

For supplements: the NMN evidence base is the most direct route to NAD+ repletion with published human bioavailability data. NMN Supplements and Japanese Research covers doses, brands, and the Yoshino and Igarashi trial data. For readers interested in the broader molecular picture of sirtuins, mTOR, AMPK, and longevity biology together, several research-grounded books on the topic are available on Amazon.

The sirtuin pathway connects directly to two other research clusters covered on Choju Lab: autophagy (SIRT1 promotes ATG protein deacetylation, linking caloric restriction to autophagy induction) and the gut microbiome (SIRT3’s role in mitochondrial function is relevant to butyrate-producing gut bacteria research). Both are covered in the autophagy article and gut-brain axis article. The three articles together represent the current research cluster on cellular aging mechanisms — sirtuins and NAD+, autophagy and fasting biology, and microbiome and SCFA signaling — each distinct but connected at the mechanistic level.